Categories: CancerNews

Mendus AB: Change in number of shares and votes in Mendus AB (publ)

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new shares being issued to Negma Group upon conversion of convertible bonds.

The issue of shares upon conversion of convertible bonds has resulted in an increase in the number of shares from 200,173,616 shares to 201,311,406 shares and an increase in the share capital by SEK 56,889.50, from SEK 10,008,680.80 to SEK 10,065,570.30.

As of February 28, 2023, the last trading day of the month, there was a total of 201,311,406 shares and votes in Mendus AB (publ).

This information is such information that Mendus AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen om handel med finansiella instrument). The information was submitted for publication through the agency of the contact persons set out below on 31 March 2023, at 08:00 am CEST.


FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com


INVESTOR RELATIONS
Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com


MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

Staff

Recent Posts

CharmHealth Innovation Challenge Returns With $10,000 Prize, Spotlights Agentic AI in Healthcare

Annual Competition Invites Innovators, Entrepreneurs and Developers to Shape the Future of Digital Health With…

56 minutes ago

CharmHealth Innovation Challenge Returns With $10,000 Prize, Spotlights Agentic AI in Healthcare

Annual Competition Invites Innovators, Entrepreneurs and Developers to Shape the Future of Digital Health With…

57 minutes ago

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026

COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of…

1 hour ago

Dr. Renuka Kulkarni Joins Gestalt as Chief Medical Officer

SPOKANE, Wash., June 18, 2025 /PRNewswire/ -- Gestalt, a leading provider of AI-powered digital pathology…

1 hour ago

Biobot Analytics Announces New Funding Round Led by Valor Equity Partners; Expands Board of Directors

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Biobot Analytics, the leader in wastewater intelligence, today…

1 hour ago

Cardiac Marker Testing Market Poised for Steady Growth, Driven by Point-of-Care Expansion

ARLINGTON, Va., June 18, 2025 /PRNewswire/ -- The global cardiac marker testing market is on…

1 hour ago